

AXINON® lipoFIT®

NMR Lipoprotein Profiling



## Cardiovascular Risk Assessment through Lipoprotein Subclass Analysis

LDL-C alone can underestimate or overestimate CVD risk.  
LDL-p and SLDL-p are more reliable predictors of CVD risk.



### Determine recommended LDL-p and SLDL-p

Several guidelines and position statements, including AACC, AACE, ADA/ACC and NLA, recommend determining LDL-p and SLDL-p for cardiovascular risk assessment.



### Experience AXINON® lipoFIT® - the first CE-marked test for LDL-p and SLDL-p determination

Comprehensive NMR lipoprotein profiling in a single test.

- ✓ LDL-p, HDL-p and subclass particle concentrations
- ✓ SLDL-p cholesterol and other subclass cholesterol
- ✓ Standard lipid panel

\* Available as a CE-labeled in vitro diagnostic product in the European Union and as Research-Use-Only product in the United States. numares' products have not yet been approved or cleared by the U.S. Food and Drug Administration.



2022\_AXINON\_lipoFIT\_Clinical\_Brochure, Version 3.0

© 2022 numares AG. All rights reserved.

USA  
198 Tremont Street #301  
Boston, MA 02116-4705  
+1 833-6862737  
mail@numares.com

Germany  
Am BioPark 9  
93053 Regensburg  
+49 941 280 949-00  
info@numares.com

[www.numares.com](http://www.numares.com)

## Cardiovascular Risk Assessment through Lipoprotein Subclass Analysis

LDL-C alone can underestimate or overestimate CVD risk. LDL-p and SLDL-p are more reliable predictors of CVD risk.

50% of patients hospitalized with confirmed clinical diagnoses of CAD have target LDL-C levels <sup>[1,2]</sup>.

### LDL-p and SLDL-p are more reliable predictors of CVD risk

- Small LDL (SLDL-p) particles are especially atherogenic <sup>[3]</sup>
- LDL-p is an independent risk factor for CVD <sup>[4-6]</sup>
- LDL-p predicts CVD risk more reliably, particularly if LDL-p and LDL-C are discordant <sup>[7-10]</sup>

### Assessment of LDL-p and SLDL-p is recommended by expert panels

Several guidelines and position statements, including AACC, AACE, ADA/ACC and NLA, recommend assessment of LDL-p and SLDL-p <sup>[11-17]</sup>.

### Treatment considerations

- A treatment target of LDL-p < 1000 nmol/L has been recommended for high-risk patients <sup>[15]</sup>
- Statins have consistently been shown to have a greater effect on LDL-C than LDL-p <sup>[16]</sup>
- More aggressive treatment might be required to reach LDL-p targets <sup>[16]</sup>

### AXINON® lipoFIT® – the first CE-marked test for LDL-p and SLDL-p determination

Comprehensive NMR lipoprotein profiling providing

- LDL-p, HDL-p and subclass particle concentrations
- SLDL-p cholesterol and other subclass cholesterol concentrations
- Standard lipid panel

### How the test works

AXINON® lipoFIT® runs on the AXINON® System, an easy-to-use, highly automated analysis system based on numares' proprietary MGS® (*Magnetic Group Signaling™*) technology and nuclear magnetic resonance (NMR) spectroscopy (600 MHz).

### Test performance

- Excellent precision (CV < 3.7%)
- Linearity and trueness demonstrated
- Throughput > 450 samples per day

1. Sachdeva A, et al., Am Heart J 2009. 157:111-117 e2.
2. Ridker PM, et al., N Engl J Med 2002. 347:1557-65.
3. Rizzo, K. et al., QJM: An Intern. Journal of Med. 2006. 99(1):1-14.
4. El Harchaoui K, et al., J Am Coll Cardiol 2007. 49:547-53.
5. Kuller L, et al., Arterioscler Thromb Vasc Biol 2002. 22:1175-1180.
6. Mora, S., et al., Circulation, 2009. 119(7): 931-9.
7. Mora, S., et al., Circulation, 2014. 129(5): 553-61.
8. Cromwell, W.C., et al., J Clin Lipidol, 2007. 1(6): 583-92.
9. Otvos JD, et al., J Clin Lipidol 2011. 5:105-13.
10. Toth PP, et al., Atherosclerosis 2014. 235:585-91.
11. Brunzell JD, et al., Diabetes Care 2008. 31:811-22.
12. Cole TG, et al., Clin Chem. 2013. 59(5):752-770.
13. Contois JH, et al., Clin Chem 2009. 55:407-19.
14. Davidson MH, et al., J Clin Lipidol 2011. 5:338-67.
15. Garber AJ, et al., Endocr Pract 2015. 21:438-47.
16. Sniderman AD. J Clin Lipidol 2008. 2:36-42.
17. Jacobson TA, et al., J Clin Lipidol 2015. 9:129-69.